The Food an Drug Administration is not going to grant a priority review to GlaxoSmithKline's experimental cancer vaccine Cervarix. Adding pressure is recent controversy surrounding its diabetes drug Avandia.
Cervarix will now have to go through a standard 10-month review, instead of going the fast-track route. GlaxoSmithKline is defending its diabetes drug after a study published in the New England Journal of Medicine said that those taking the drug are at greater risks of heart attacks.
GlaxoSmithKline expects to market the drug Cervarix in the United States sometime in 2008.










